Description
Introduction to Futibatinib 4mg Tablet:
Futibatinib 4mg Tablet is an oral, irreversible fibroblast growth factor receptor (FGFR) inhibitor used in targeted oncology, specifically for the treatment of FGFR2-rearranged cholangiocarcinoma (bile duct cancer).
This tablet is taken by mouth, exactly as prescribed by your doctor. Your doctor will determine the appropriate dose and duration of treatment based on your specific genetic and clinical profile, since this medicine is used only in genetically selected cancers with confirmed FGFR2 rearrangements.
Uses of Futibatinib 4mg Tablet:
- FGFR2-rearranged cholangiocarcinoma
Benefits of Futibatinib 4mg Tablet:
This Tablet offers durable FGFR inhibition in FGFR-driven malignancies. Because it binds irreversibly to FGFR1-4 kinases, it can overcome the resistance that sometimes develops with reversible FGFR inhibitors, making it a valuable option for patients whose cancer has this specific genetic alteration.
Mechanism of Action of Futibatinib 4mg Tablet:
This tablet works by irreversibly inhibiting FGFR1-4 kinases, blocking the signaling pathways that drive tumor cell proliferation and the formation of new blood vessels that feed tumors (angiogenesis). For more clinical details, refer to MedlinePlus Drug Information, a trusted resource from the U.S. National Library of Medicine.
Side Effects and Precautions:
Common side effects include hyperphosphatemia (elevated phosphate levels), diarrhea, fatigue, and eye-related toxicity. Regular monitoring of serum phosphate levels and routine ophthalmologic examinations are recommended throughout treatment to catch and manage these effects early.
This information is intended for educational purposes only and should not replace clinical judgment. Treatment decisions must always be made by qualified healthcare professionals.
Reviews
There are no reviews yet.